ArticleACS measurement science au2026
Fully 3D-Printed Sampling-to-Detection Electrochemical Platform for Point-of-Care Measurement of Salivary Uric Acid.
Article in ACS measurement science au, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This research presents an innovative all-in-one 3D-printed electrochemical biosensor for noninvasive detection of uric acid in saliva. Uric acid is a key biomarker for monitoring disorders such as gout and kidney disease as well as assessing the progression of metabolic conditions. The 3D-printed platform integrates a microwell, saliva collection module, and a three-electrode system, including carbon black and Prussian-blue-modified electrodes with immobilized uricase, into a single compact device, streamlining the sampling-to-detection workflow. Initial optimization using screen-printed electrodes on polyester films with differential pulse voltammetry established baseline performance, while the fully integrated 3D-printed system, with the incorporation of uricase, achieved detection limits of 0.09 μM in phosphate-buffered saline and 0.1 μM in 20% diluted saliva. Comparative analysis with high-performance liquid chromatography confirmed the accuracy and reliability of the measurements. By combining nanomaterial-enhanced electrodes, enzymatic recognition, and additive manufacturing, this platform offers a portable, user-friendly, and low-cost solution for point-of-care uric acid monitoring. The integrated design minimizes sample handling, prevents contamination, and enables hygienic, noninvasive collection. This approach facilitates rapid diagnostic testing and real-time health monitoring, providing actionable information for personalized patient care. Overall, the fully 3D-printed biosensing system represents a significant advance in electrochemical biosensors, demonstrating the potential to improve the clinical management of uric acid-related conditions while enabling scalable, accessible, and point-of-care diagnostics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.